Navigation Links
Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting

SAN FRANCISCO, Nov. 11 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. To date MagniFuse has been used in 40 spinal surgeries in the United States.

"Our strategy is to utilize our platform technologies to develop procedure-specific products to address critical unmet surgical needs and we are very excited to be highlighting our MagniFuse platform at NASS," said Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer. "By utilizing our MagniFuse product line in posterior cervical, posterolateral and spinal deformity procedures, Osteotech is targeting a significant segment of the spinal therapy area. Feedback from surgeons that have used MagniFuse to date indicates the differentiated characteristics and capabilities supported by our MagniFuse technology have been well received, and we believe we are strongly positioned to become a market leader."

MagniFuse is a patented, next-generation technology platform that supports a family of high-performance, procedure-specific products that provide for simplified, precision grafting when injury or disease creates a need for bone fusion or new bone growth.

"In addition, we are also looking forward to showcasing our leading-edge FacetLinx(TM) Fusion Technology and Plexur M(TM) Innovative Grafting at NASS," continued Mr. Owusu-Akyaw. "Similar to MagniFuse, these products have received very positive responses in the market and we believe they will both play an important role in our future success. Our goal at Osteotech is to continue to commercialize proprietary biologics designed to address the unmet needs of the surgeon community and we believe these introductions illustrate our ability to successfully execute this strategy. We are pleased to share them directly with the physician community through NASS this week."

New MagniFuse Technology Products

Osteotech is showcasing three procedure-specific forms for three different spine therapy areas in the Company's booth at NASS: PC (posterior cervical), SD (spinal deformity) and PL (posterolateral).

  • MagniFuse PC (posterior cervical) - Posterior cervical fusion is a surgical procedure to stop motion between two or more vertebrae that may be causing neck pain or damage to the nerves that extend into the upper extremities.
  • MagniFuse SD (spinal deformity) - Spinal deformities, or curves in the spine, often develop during growth in adolescence or as a result of aging. MagniFuse will be utilized in the treatment of scoliosis, a frontal spinal deformity where the normal straight alignment of the spine from the front is affected by a curve to the left or right.
  • MagniFuse PL (posterolateral) - Posterolateral fusion involves placing bone graft in the posterolateral portion of the spine. This procedure may be recommended as a surgical treatment option for patients with a condition causing spinal instability, such as degenerative disc disease, spondylolisthesis or spinal stenosis, which has not responded to conservative treatment measures (rest, physical therapy or medication).

MagniFuse Technology Platform

Osteotech's MagniFuse technology platform and related products offer unique, differentiating features compared with other bone grafts on the market:

  • As a result of Osteotech's proprietary manufacturing and processing technology, MagniFuse utilizes a highly active biologic material, derived from an allograft source material containing a higher concentration of multiple natural human growth factors.
  • This formulation is delivered in a unique, resorbable, mesh bag delivery-containment system that is sized specifically for the procedure application, eliminating the graft migration-related issues facing competitive products. It is also radiopaque, enabling surgeons to confirm both intra- and post-operation placement of the graft.
  • The combination of MagniFuse's formulation and delivery system provides an optimized scaffold comprised of 100% bone material that produces targeted bone formation, as evidenced by our clinical data to date.
  • Osteotech worked with a team of recognized spine surgeons and used their feedback in the development of the specific procedural forms within the MagniFuse line of products based on sizing and surgical techniques used in spinal surgeries.

Plexur M Innovative Grafting

Plexur M, a biocomposite combination of cortical bone fibers and resorbable polymers, may be used in a variety of orthopedic procedures as a bone void filler. Developed utilizing the Company's proprietary Plexur® technology, Plexur M offers a number of unique characteristics for orthopedic surgeons:

  • Plexur M is pliable and moldable when heated, and can be shaped to specifically fit most defects.
  • Plexur M provides porosity for bone growth after implantation and is fully resorbed by the body during the remodeling process.
  • Plexur M hardens at body temperature when applied within the body allowing surgeons to quickly move to the next step in the surgery.

The Plexur technology platform is a unique and patented combination of polymer and cortical bone fibers that supports a family of procedure-specific products targeted for use in a variety of orthopedic surgeries. Plexur technology-based products have been clinically shown to completely resorb into the body within six to twelve months and to be replaced by host bone. Plexur technology offers improved handling and an effective osteoconductive matrix with high levels of porosity that provides a broad surface area for new cell growth. Plexur is supported by more than 20 patents and patent applications and is the platform technology that supports Plexur P(TM) used in a variety of trauma and reconstructive surgeries and focused on foot and ankle procedures as well as Plexur M.

FacetLinx Fusion Technology

Facet joint disorders are among the most common of all the recurrent, disabling low back problems that have serious symptoms and disability. FacetLinx is a patent-pending spinal allograft product that treats mechanical and facet-driven back pain by fixating the facet joints or may augment standard instrumented and non-instrumented fusion, offering patients stability with minimum additional risks. FacetLinx offers a number of differentiating advantages over other facet fusion devices:

  • FacetLinx is quick, simple and has immediate efficacy, with reduced potential complications.
  • The FacetLinx system's less invasive design provides a cruciform shape that is more stable and will resist motion to thus aid in immediate back pain relief.
  • The FacetLinx system facilitates direct access to the cancellous bone on both sides of the facet joint to facilitate fusion.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at

Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of November 11, 2009 and the Company does not intend to update this information.

SOURCE Osteotech, Inc.

SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Osteotech Reports Third Quarter 2009 Financial Results
2. Osteotechs MagniFuse(TM) Technology Used in First U.S. Surgery
3. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
4. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
5. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
6. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
7. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
8. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
9. New Campaign Highlights How Medical Products Distributors Streamline Healthcare
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Post Your Comments:
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
Breaking Medicine News(10 mins):